Dorui pharmaceutical: clinical approval documents for subsidiaries to purchase new drugs
Dorui pharmaceutical announced that ruidilian pharmaceutical, a holding subsidiary, signed a technology transfer contract with Henan University of traditional Chinese medicine, which agreed that Henan University of traditional Chinese medicine would transfer all patents and non patented technologies related to the clinical trial approval notice of "Yifei Jisheng Granule" and its new drug projects to ruidilian pharmaceutical.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives
In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow
May 09, 2024 12:18 PM
Jan 06, 2023 08:30 AM
Nov 16, 2022 05:19 PM
Nov 08, 2022 08:32 AM
Nov 07, 2022 04:27 PM
Automotive · Analysis
Research on the Market Entry of EVs in Malaysia
In 2023, Malaysia’s Prime Minister, Anwar Ibrahim, set an ambitious target to transition 15% of vehicles on Malaysian roads to electric vehicles (EVs) by 2030, attracting a range of international brands into the country. For Chinese companies, this presents an opportunity. But how should they approach entering the Malaysian automotive market, the third-largest manufacturing hub in Southeast Asia?
Sep 27, 2024 06:03 PM
See more
Read next
Insight
In-depth
Insight
In-depth
Automotive · Analysis
360 Billion: How Can Chinese Companies Grow Together with Africa
Sep 27, 2024 06:30 PM
Insight
In-depth